1. Fig. 6. PVSRIPO oncolysate–pulsed DCs generate tumor antigen–specific CTL immunity in vitro.
PVSRIPO oncolysate–pulsed DCs generate tumor antigen–specific CTL immunity in vitro. Primary human DCs coincubated with SUM149, MDA-MB231, LNCaP, or DM6 oncolysate stimulate tumor antigen–specific T cell responses in vitro. (A) Schema of the assay. (B) T cells were cocultured with oncolysate-pulsed autologous DCs, and the stimulated effector T cells were then harvested and tested in a CTL assay against the corresponding tumor cells (red bars), autologous DCs transfected with RNA that encodes for a relevant tumor antigen (black bars; positive control), or autologous DCs transfected with RNA that encodes for an irrelevant tumor antigen (white bars; negative control). Each bar represents mean % specific lysis and SD of triplicate samples. Statistical significance comparing autologous DCs expressing either the relevant or irrelevant tumor antigen for each panel in (B) was calculated using paired two-tailed Student’s t test. A probability of less than 0.05 (P < 0.05) is considered statistically significant. Panel SUM149 DC targets, P = 0.04; panel LNCaP DC targets, P = ; panel MDA-MB231 DC targets, P = 0.01; panel DM6 DC targets, P = EGFR, epidermal growth factor receptor; PSA, prostate-specific antigen.
Michael C. Brown et al., Sci Transl Med 2017;9:eaan4220
Published by AAAS